# A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

> **NCT05017116** · PHASE1 · COMPLETED · sponsor: **Suzhou Ribo Life Science Co. Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** RBD1016
- **DRUG:** Placebo
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT05017116
- **Lead sponsor:** Suzhou Ribo Life Science Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-09
- **Primary completion:** 2023-10-25
- **Final completion:** 2023-10-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05017116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05017116, "A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05017116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*